Exploring Elon Musk’s skinny jab: A potential solution for obesity in South Africa?

Semaglutide, a drug marketed as Wegovy or Ozempic that was initially designed for diabetic patients to control blood sugar levels, has garnered attention for its potential weight loss effects. Notably, technology entrepreneur Elon Musk, hailing from South Africa, attributed his transformed physique, lauded by a fan as “ripped,” to fasting and the use of Wegovy. Muhammed Vally, Head of the Division of Clinical Pharmacy and Lecturer at Wits University, highlighted that clinical trials demonstrated that non-diabetic individuals who took Semaglutide experienced an average weight loss of 14.9%, in contrast to 2.4% in the placebo group. In an interview with Biznews Vally, however, stresses that the medication should not be considered a standalone solution and must be complemented with a proper diet and exercise regimen to maximise its benefits. It is important to note that Semaglutide may cause side effects such as nausea and diarrhoea. Despite these considerations, Vally believes that exploring the potential of this medication to address obesity is worth considering. Learn more about your ad choices. Visit megaphone.fm/adchoices